ATH 33.3% 0.4¢ alterity therapeutics limited

Ann: Notice Under Section 708A, page-45

  1. 102 Posts.
    lightbulb Created with Sketch. 21
    Hi Stockman,

    Great post and thank you. In relation to the open label trial in July, surely some improvement would be classed as being better than no improvement at all? and yes perhaps a longer treatment timeframe would be more beneficial perhaps. But despite all the finickiness in the market, surely that should be positive enough o start our journey north ? Still banking on some positive news after the neurology conference next month!

    Have a great weekend!
    GLTAH
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.